Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 5—May 2023
Dispatch

Characteristics and Treatment of Gordonia spp. Bacteremia, France

Alia Barthel1, Axel Ursenbach1, Charlotte Kaeuffer1, Christelle Koebel, Alain Gravet, Dominique De Briel, Jacqueline Dubois, Elina Haerrel, Estelle Rougier2, and Victor Gerber13Comments to Author 
Author affiliations: Hôpitaux universitaires de Strasbourg, Strasbourg, France (A. Barthel, A. Ursenbach, C. Koebel, E. Rougier); Groupement Hospitalier de Mulhouse et Sud-Alsace, Mulhouse, France (C. Kaeuffer, A. Gravet); Hôpitaux Civils de Colmar, Colmar, France (D. de Briel, J. Dubois, E. Haerrel, V. Gerber)

Main Article

Table 1

Description of Gordonia bacteremia cases, 2010–2021, France*

Patient no. Patient age/sex Immune deficiency factors CVC type Clinical signs Species (no. positive samples) AMR Treatment Time, d CVC removed
Favorable outcome†
1 36 y/M HIV,
nephrotic syndrome		 HD CVC inflammation Gordonia sp. (1) None None 0 Yes
2 3 y/M Hemopathy,
corticosteroid,
methotrexate		 Central
port		 Fever G. bronchialis (1)‡ None CAZ, AMC 7 No
3 86 y/M None None Fever, cough G. sputi (1)‡ None AMC, 3GC 10 NA
4 56 y/F HIV None Fever G. sputi (1) ‡ None 3GC 10 NA
5 67 y/F Malnutrition, hemopathy, cancer TCVC Acute kidney failure Gordonia sp. (1) None 3GC, VAN 15 Yes
6 75 y/M None None Fever, chills G. aichiensis (1)‡ ERY, FA, FOF PEN G, AMOX 15 NA
7 42 y/M Cirrhosis
splenectomy, corticosteroid		 Central
port		 Fever G. sputi (2) PEN, SMX TZP, VAN 15 No
8
 2y/M
 None
 None
 Knee arthritis
 Gordonia sp. (1)‡
 §
 CFZ, AMK; Tr 2¶: cefaclor
 5 NA
30
Relapse#
9 3 mo/M Nephrotic syndrome,
low IgG		 TCVC Fever G. bronchialis (1) ERY, FA, FOF AMOX; Tr 2¶: JM, polyvalent Ig 8 Yes
5
10 61 y/F Immunosuppressive regimen,
corticosteroid,
malnutrition		 Central port Fever,
angiocolitis,
port inflammation		 G. sputi (2) § CPFX, TZP; Tr 2¶: IMP, AMK, VAN; Tr 3¶: 3GC, GEN 15 No
10
7

*3GC, 3rd generation cephalosporin; AMC, amoxicillin-clavulanic acid; AMK, amikacin; AMOX, amoxicillin; AMR, antimicrobial resistance; CAZ, ceftazidime; CFZ, cefazolin; CPFX, ciprofloxacin; CVC, central venous catheter; ERY, erythromycin; FA, fusidic acid; FOF, fosfomycin; GEN, gentamicin; HD, hemodialysis; IMP, imipenem; JM, josamycin; NA, not applicable; PEN, penicillin; SMX, sulfamethoxazole; TCVC, tunneled CVC; TZP, piperacillin/tazobactam; VAN, vancomycin. †Favorable outcome required clinical and biologic cure and repeated negative blood sample (when available), without relapse until the end of the study period (May 31, 2022). ‡In medical record, Gordonia sp. was considered a contaminant with no clinical significance. §Antimicrobial susceptibility testing not performed. ¶Treatment regimens after relapse. #Relapses through May 31, 2022.

Main Article

1These authors contributed equally to this article.

2Current affiliation: Hôpital Saint-Antoine, Assistance Publique des Hôpitaux de Paris, Paris, France.

3Current affiliation: Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Page created: March 01, 2023
Page updated: April 19, 2023
Page reviewed: April 19, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external